Perhaps she didn't step up as would be expected of a senior executive when Esra hit the fan - Harry coming back full time but not as CEO and who has certainly stepped up - possibly its a game of musical chairs with only so many senior roles/salaries to go around. As for who will run phase 2/3 I think we will find our new ceo's credentials are heavily weighted towards someone who is able to prove their ability to push a drug through trials to commericialbility......rather than being a pure business type from an unrelated industry......I get the feeling this new CEO will be very hands on - something as it turns out our last CEO wasn't (wasn't at the negotiation table or the lab) ---unless you count the hands in the till!!!
new ceo and board 'business model', page-64
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $16.54K | 5.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 96791453 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 58594028 | 16 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |